Shares of XBiotech Inc (NASDAQ:XBIT) have been assigned an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.
Brokers have set a 12-month consensus price target of $13.00 for the company and are anticipating that the company will post ($0.15) EPS for the current quarter, according to Zacks. Zacks has also given XBiotech an industry rank of 62 out of 256 based on the ratings given to its competitors.
XBIT has been the topic of several research reports. BidaskClub lowered XBiotech from a “buy” rating to a “hold” rating in a research report on Monday, April 15th. Piper Jaffray Companies set a $120.00 target price on bluebird bio and gave the stock a “hold” rating in a research report on Friday, June 14th.
Shares of XBiotech stock traded down $0.36 during trading hours on Friday, reaching $7.40. 1,665 shares of the company’s stock were exchanged, compared to its average volume of 250,206. XBiotech has a 52-week low of $2.13 and a 52-week high of $11.74. The company has a market capitalization of $280.24 million, a price-to-earnings ratio of -12.93 and a beta of 0.49. The company’s fifty day moving average is $7.71.
XBiotech (NASDAQ:XBIT) last issued its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter. On average, analysts expect that XBiotech will post -0.61 earnings per share for the current fiscal year.
In related news, major shareholder Fondation Rennes acquired 1,200,000 shares of the business’s stock in a transaction on Tuesday, June 4th. The shares were bought at an average cost of $8.25 per share, with a total value of $9,900,000.00. Following the completion of the transaction, the insider now directly owns 5,110,282 shares of the company’s stock, valued at approximately $42,159,826.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 33.40% of the company’s stock.
Large investors have recently added to or reduced their stakes in the business. Birchview Capital LP acquired a new position in XBiotech in the first quarter worth about $110,000. Marshall Wace LLP acquired a new position in XBiotech in the first quarter worth about $682,000. Finally, Tibra Equities Europe Ltd acquired a new position in XBiotech in the first quarter worth about $750,000. 7.05% of the stock is currently owned by institutional investors.
XBiotech Company Profile
XBiotech Inc, a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is bermekimab, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer.
See Also: How to Trade Using Analysts Ratings
Get a free copy of the Zacks research report on XBiotech (XBIT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.